Your browser doesn't support javascript.
loading
Limited clinical activity of nilotinib and sorafenib in FIP1L1-PDGFRA positive chronic eosinophilic leukemia with imatinib-resistant T674I mutation.
Metzgeroth, G; Erben, P; Martin, H; Mousset, S; Teichmann, M; Walz, C; Klippstein, T; Hochhaus, A; Cross, N C P; Hofmann, W-K; Reiter, A.
Leukemia ; 26(1): 162-4, 2012 Jan.
Article in En | MEDLINE | ID: mdl-21818111
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Piperazines / Pyridines / Pyrimidines / Benzenesulfonates / Hypereosinophilic Syndrome / Receptor, Platelet-Derived Growth Factor alpha / MRNA Cleavage and Polyadenylation Factors / Mutation / Antineoplastic Agents Limits: Adolescent / Adult / Aged / Humans / Male / Middle aged Language: En Journal: Leukemia Journal subject: HEMATOLOGIA / NEOPLASIAS Year: 2012 Document type: Article Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Piperazines / Pyridines / Pyrimidines / Benzenesulfonates / Hypereosinophilic Syndrome / Receptor, Platelet-Derived Growth Factor alpha / MRNA Cleavage and Polyadenylation Factors / Mutation / Antineoplastic Agents Limits: Adolescent / Adult / Aged / Humans / Male / Middle aged Language: En Journal: Leukemia Journal subject: HEMATOLOGIA / NEOPLASIAS Year: 2012 Document type: Article Country of publication: